Splicing Dysregulation Contributes to the Pathogenicity of Several F9 Exonic Point Variants by Katneni, Upendra K. et al.
Cleveland State University
EngagedScholarship@CSU
Biological, Geological, and Environmental Faculty
Publications
Biological, Geological, and Environmental Sciences
Department
6-2019
Splicing Dysregulation Contributes to the
Pathogenicity of Several F9 Exonic Point Variants
Upendra K. Katneni
U.S. FDA
Aaron Liss
U.S. FDA
David Holcomb
U.S. FDA
Nobuko H. Katagiri
U.S. FDA
Ryan Hunt
U.S. FDA
See next page for additional authors
Follow this and additional works at: https://engagedscholarship.csuohio.edu/scibges_facpub
Part of the Biology Commons
How does access to this work benefit you? Let us know!
This Article is brought to you for free and open access by the Biological, Geological, and Environmental Sciences Department at
EngagedScholarship@CSU. It has been accepted for inclusion in Biological, Geological, and Environmental Faculty Publications by an authorized
administrator of EngagedScholarship@CSU. For more information, please contact library.es@csuohio.edu.
Recommended Citation
Katneni, Upendra K.; Liss, Aaron; Holcomb, David; Katagiri, Nobuko H.; Hunt, Ryan; Bar, Haim; Ismail, Amra; Komar, Anton A.;
and Kimchi‐Sarfaty, Chava, "Splicing Dysregulation Contributes to the Pathogenicity of Several F9 Exonic Point Variants" (2019).
Biological, Geological, and Environmental Faculty Publications. 97.
https://engagedscholarship.csuohio.edu/scibges_facpub/97
Authors
Upendra K. Katneni, Aaron Liss, David Holcomb, Nobuko H. Katagiri, Ryan Hunt, Haim Bar, Amra Ismail,
Anton A. Komar, and Chava Kimchi‐Sarfaty
This article is available at EngagedScholarship@CSU: https://engagedscholarship.csuohio.edu/scibges_facpub/97
Received: 10 May 2019 | Accepted: 10 June 2019
DOI: 10.1002/mgg3.840
ORIGINAL ARTICLE
Molecular Genetics & Genomic Medicine WILEY
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Abstract
Background: Pre-mRNA splicing is a complex process requiring the identification 
of donor site, acceptor site, and branch point site with an adjacent polypyrimidine 
tract sequence. Splicing is regulated by splicing regulatory elements (SREs) with 
both enhancer and suppressor functions. Variants located in exonic regions can im- 
pact splicing through dysregulation of native splice sites, SREs, and cryptic splice 
site activation. While splicing dysregulation is considered primary disease-inducing 
mechanism of synonymous variants, its contribution toward disease phenotype of 
non-synonymous variants is underappreciated.
Methods: In this study, we analyzed 415 disease-causing and 120 neutral F9 exonic 
point variants including both synonymous and non-synonymous for their effect on 
splicing using a series of in silico splice site prediction tools, SRE prediction tools, 
and in vitro minigene assays.
Results: The use of splice site and SRE prediction tools in tandem provided better 
prediction but were not always in agreement with the minigene assays. The net effect 
of splicing dysregulation caused by variants was context dependent. Minigene assays 
revealed that perturbed splicing can be found.
Conclusion: Synonymous variants primarily cause disease phenotype via splicing 
dysregulation while additional mechanisms such as translation rate also play an im- 
portant role. Splicing dysregulation is likely to contribute to the disease phenotype of 
several non-synonymous variants.
KEYWORDS
hemophilia B, in silico splicing analysis, in vitro minigene assay, splicing dysregulation, synonymous 
variants
1 | INTRODUCTION
Pre-mRNA splicing is the natural process of excision of non- 
coding introns and joining of exons (Caminsky, Mucaki, & 
Rogan, 2015). Splicing requires the detection of acceptor site
(or 3' splice site) and donor site (or 5' splice site) located at 
the intron-exon junctions and branch point site with adjacent 
polypyrimidine tract sequence located about 18—40 nucleo- 
tides upstream of acceptor site in intron by the spliceosome 
machinery (Cartegni, Chew, & Krainer, 2002). Splicing
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited.
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machinery primarily consists of five small nuclear ribonuc- 
leoproteins (snRNPs; U1, U2, U4, U5, and U6) and several 
other proteins (Will & Lührmann, 2001). The consensus se- 
quence of donor site is 10 nucleotides long and extends from 
-3 in exon to +6 in intron with position 0 being the first 
nucleotide of intron. The consensus sequence of acceptor site 
is 28 nucleotides long extending from position -25 in intron 
to +2 in exon. Within these consensus sequences, for donor 
sites, nucleotides G and T are highly conserved at positions 
0 and +1 and nucleotides A and G are predominant at posi- 
tions -2 and -1. For acceptor sites, nucleotides A and G are 
highly conserved at positions -1 and 0 and nucleotide G is 
predominant at position +1 (Caminsky et al., 2015; Cartegni 
et al., 2002). The remaining positions in these consensus 
sequences are less stringent and the degree of consensus in 
these positions determines the strength of the natural splice 
sites and the ability of snRNPs to recognize them (Caminsky 
et al., 2015). In addition, 6-8 nucleotides long splicing regu- 
latory elements (SREs) located in both exons and introns act 
as binding sites for splicing activator or repressor proteins 
and play an important role in regulation of splicing. Based 
on the location and their effect on splicing, SREs are classi- 
fied as exonic splicing enhancers or silencers (ESEs or ESSs) 
and intronic splicing enhancers or silencers (ISEs or ISSs; 
Caminsky et al., 2015). Enhancer SREs and silencer SREs 
exert their action by acting as binding sites for serine-arginine 
rich (SR) proteins and heterogeneous nuclear ribonucleop- 
rotein (hnRNP), respectively (Chen, Kobayashi, & Helfman, 
1999; Graveley, 2000).
The human F9 gene (OMIM: 300746) is located on the 
long arm of X-chromosome (Xq27.1-q27.2) and encodes a 
serine protease zymogen; coagulation factor IX (FIX; Anson 
et al., 1984; Rallapalli, Kemball-Cook, Tuddenham, Gomez, 
& Perkins, 2013). F9 gene spans about 34 kilobase pairs in 
length and is comprised of eight exons and seven introns 
(Anson et al., 1984). The primary F9 transcript encodes a 
461 amino acid (aa) long pre-pro-protein which is processed 
to yield a 415 aa mature FIX.
The partial or complete absence of FIX leads to the blood 
clotting disorder, hemophilia B (Bowen, 2002). Based on the 
level of FIX deficiency, hemophilia B is classified as severe 
(<1% of normal), moderate (1%—5% of normal), and mild 
(5%—40% of normal; White et al., 2001). Hemophilia B is 
primarily an inherited X-linked recessive disorder caused by 
variants in F9 gene. The current version of Center for Disease 
Control and Prevention's (CDC) Hemophilia B Mutation 
Project (CHBMP) database (f9-CHBMP-v5-5-5-15) contains 
1,131 F9 variants (Li, Miller, Payne, & Craig Hooper, 2013). 
These F9 variants are classified as missense variants (657, 
58.1%), nonsense variants (91, 8%), intronic variants caus- 
ing splice site changes (106, 9.4%), frameshift variants (182, 
16.1%), large structural changes of >50 base pairs (bp; 33, 
2.9%), small structural changes (23, 2%), promoter variants
(25, 2.2%), 3'Untranslated region variants (4,0.4%), and syn- 
onymous variants (10,0.9%). Of these, missense variants and 
synonymous variants in exonic regions are point variants that 
involve single-nucleotide substitution and make up majority 
(59%) of F9 variants.
Synonymous variants do not alter the underlying aa se- 
quence and are considered to primarily cause disease by 
altering splicing of pre-mRNA transcript (Hunt, Simhadri, 
Iandoli, Sauna, & Kimchi-Sarfaty, 2014). Missense (non- 
synonymous) variants alter the aa sequence of the protein 
which is considered to be the main causative mechanism of 
the disease. However, recent studies revealed that significant 
proportion of these variants also affect splicing (Caminsky 
et al., 2015; Soukarieh et al., 2016; Sterne-Weiler, Howard, 
Mort, Cooper, & Sanford, 2011), thus suggesting another, yet 
so far, underappreciated role of the altered splicing in the or- 
igin of the disease.
Synonymous and non-synonymous point variants in ex- 
onic regions that alter sequences of splice sites and SREs 
dysregulate the splicing of pre-mRNAs. Depending on the 
context of variant, splicing disruption by variants can lead to 
either exon skipping, intron inclusion, mis-splicing, or leaky 
splicing (Caminsky et al., 2015). Ideally, the effect of vari- 
ants on splicing is best characterized by analyzing the RNA 
transcripts isolated from patient's clinical sample. In the case 
of hemophilia B, F9 is primarily expressed in liver and anal- 
ysis of RNA transcripts from peripheral blood to assess splic- 
ing is not reliable (Green, Rowley, & Giannelli, 2003). Since 
it is not feasible to obtain primary hepatocytes, researchers in 
the field of hemophilia B have to rely on in silico prediction 
tools and in vitro assays to assess the impact of F9 variants 
on pre-mRNA splicing.
In this study, we employed a series of in silico splicing 
analysis tools in conjunction with in vitro minigene assays 
to assess the effect of F9 exonic variants and neutral vari- 
ants on pre-mRNA splicing. Results from our study showed 
that splicing dysregulation contributes to disease phenotype 
of several F9 non-synonymous variants. In silico splice site 
and SRE prediction tools in tandem better predicted the splic- 
ing dysregulation caused by variants; however, outcome of 
splicing dysregulation seems to be influenced by several ad- 
ditional factors. In vitro minigene assay is an effective tool 
to assess the effect of splicing dysregulation when clinical 
samples are not available.
2 | MATERIALS AND METHODS
2.1 | Database construction
Disease-associated exonic single-nucleotide variants in F9 
gene were obtained from databases described by Hamasaki- 
Katagiri et al. (Hamasaki-Katagiri et al., 2013), the CDC 
Hemophilia B Mutation Project database (http://www.cdc.
KATNENI et al.
gov/ncbddd/hemophilia/champs.html; Li et al., 2013) and 
EAHAD FIX Gene Variant Database (http://www.factorix. 
org/; Rallapalli et al., 2013). F9 neutral single-nucleotide 
variants were extracted from NCBI dbSNP (https://www. 
ncbi.nlm.nih.gov/snp; Reference sequence: NM_000133.3; 
Sherry et al., 2001). Only unique single-nucleotide variants 
in the open reading frame (ORF) for which both genetic and 
clinical characterization data are available were included in 
the database; insertions/deletions, frameshift variants, and 
nonsense variants were excluded. F9 variant database gener- 
ated based on these criteria included a total of 535 unique 
exonic point variants (Table 1; Table S1), of these, 415 are 
disease-causing (409 non-synonymous and six synonymous) 
and 120 are neutral (64 non-synonymous and 56 synony- 
mous). Variants of all three severities (mild, moderate, and 
severe) are collectively considered “disease-associated” vari- 
ants for the current study. The nomenclature for the variants 
in the database and manuscript was based on the recent guide- 
lines for genetic variants in hemostasis (Goodeve, Reitsma, 
& McVey, 2011).
2.2 | In silico analysis using splice site 
prediction tools
To study the effect of F9 exonic disease-causing and neu- 
tral variants on native splice site disruption and/or cryp- 
tic splice site creation/activation, we employed NNSplice, 
MaxEntScan (MES), SpliceSiteFinder-like (SSF-like), and 
Human Splicing Finder (HSF) splice site prediction tools 
that are included in the Alamut visual software (Interactive 
Biosoftware, Rouen, France. https://www.interactive-bioso
ftware.com/alamut-visual/). These tools employ different 
methods to predict splice sites: NNSPLICE employs two 
“neural networks” that were trained on consensus splice 
sites, while also considering dinucleotide frequencies due
TABLE 1 Exonic distribution of F9 disease-causing and neutral
variants analyzed in the study
Exon
Disease-
causing non-
synonymous
variants
Disease-
causing
synonymous
variants
Neutral
non-
synonymous
variants
Neutral
synonymous
variants
1 7 1 10 3
2 59 1 13 4
3 8 0 0 2
4 50 0 2 4
5 37 2 3 7
6 34 2 10 6
7 33 0 6 7
8 181 0 20 23
Total 409 6 64 56
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to the strong correlation between neighboring nucleotides in 
splice site consensus sequences (Reese, Eeckman, Kulp, & 
Haussler, 1997). MES scores sequences for splice sites by em- 
ploying “maximum entropy principle” that takes into account 
adjacent and nonadjacent position dependencies in consensus 
splice sites (Yeo & Burge, 2004). SSF-like and HSF employ 
“position weight matrices” constructed from aligned consen- 
sus sequences to weigh each nucleotide in a sequence and 
uses the sum of individual nucleotide's weights to derive its 
potential splice site strength (Desmet et al., 2009; Shapiro & 
Senapathy, 1987). To assess the splice site changes by these 
in silico splice site prediction tools, for each disease-causing 
or neutral variant, we recorded their effect on corresponding 
natural splice sites by recording wild-type and variant predic- 
tion scores (Table S2). We also recorded any cryptic sites that 
the variant created or strengthened significantly and are com- 
parable to or stronger than their corresponding native site. For 
nucleotide substitutions located within consensus splice site 
sequences, 10% reduction in score is generally interpreted to 
affect splicing (Tang, Prosser, & Love, 2016). Whereas, for 
those located outside the consensus splice site sequences, no 
clear cutoff values were established. The context-based out- 
come of splicing dysregulation by variants located outside 
consensus splice site sequences in our study also underlined 
the difficulty to establish threshold score changes for assess- 
ing such variants by in silico splice site tools. For the current 
study, disease-causing or neutral variants were designated to 
affect splicing if they disrupted a native splice site (≥10% 
score decrease) or activated/created a strong cryptic site 
(≥90% of corresponding native site score). The predictions 
of creation/activation of cryptic acceptor sites in exon 1 and 
cryptic donor sites in exon 8 were not considered.
2.3 | In silico analysis using SRE
prediction tools
To study the effect of F9 exonic disease-causing and neu- 
tral variants on SREs, we employed ESRseq, HEXplorer, 
and EX-SKIP prediction tools. ESRseq assigned scores to all 
possible hexamer sequences and designated them as enhanc- 
ers or silencers based on their effect on splicing in minigene 
experiments performed in HEK293tTA cells. The effect of 
variants on SREs, thereby on splicing, is predicted by cal- 
culating the net ESRseq score change of hexamer sequences 
overlapping the variants (Ke et al., 2011). HEXplorer also 
assigned scores (Z_EI scores) to hexamer sequences, but 
the difference from ESRseq is that calculation of scores is 
based on hexamer frequencies in 100 nucleotides of exonic 
and intronic sequences flanking the known 5'splice sites. 
Similar to ESRseq, HEXplorer also predicts the effect of 
variants on splicing by calculating the net change in hexamer 
scores affected by variants (Erkelenz et al., 2014). ESRseq 
and HEXplorer scores varied significantly in the absolute
KATNENI et al.WILEY Molecular Genetics & Genomic Medicine___
values assigned to the hexamer sequences. However, for 
both tools, a net negative score would indicate the disrup- 
tion of ESEs and/or creation of ESSs leading to exon skip- 
ping. EX-SKIP tool (http://ex-skip.img.cas.cz/) combines the 
predictions of several individual SRE prediction tools (PESE 
and PESS, FAS-ESS, RESCUE-ESE, EIE and IIEs, NI-ESE, 
and NIESS) for the presence of ESEs and ESSs and assigns 
scores based on their relative density (Raponi et al., 2011). 
Further, a ratio of ESS/ESE scores of variant over wild-type 
sequence (EX-SKIP ratio) is calculated and numbers >1 are 
considered predictive of increased exon skipping.
2.4 | In vitro minigene assays
In vitro evaluation of selected F9 disease-causing and neu- 
tral variants for their effect on splicing was performed using 
minigene reporter constructs generated from pTBNde(min) 
plasmid (Pagani et al., 2003). For the generation of reporter 
constructs, wild-type or variant F9 exon sequences along 
with ~300 bp flanking intron sequences were direction- 
ally cloned. Transfection experiments were performed in 
HEK293 cells. All minigene reporters were transfected si- 
multaneously using Lipofectamine 3000 reagent (Thermo 
Fisher Scientific, Waltham, MA). Total RNA was isolated 
24 hr posttransfection using RNeasy Plus Mini Kit (Qiagen, 
Germantown, MD) and reverse transcription was performed 
using High-Capacity cDNA Reverse Transcription Kit 
(Thermo Fisher Scientific). PCR amplification was per- 
formed with Platinum Hot Start PCR Master Mix (Thermo 
Fisher Scientific) using Alfa2-3 forward primer; 5'- 
CAACTTCAAGCTCCTAAGCCACTGC-3' and Bra2 re- 
verse primer; 5'-GTCACCAGGAAGTTGGTTAAATCA-3' 
(Fernandez Alanis et al., 2012). PCR reactions were limited 
to 25 cycles to stop the reaction in exponential phase of am- 
plification. To visualize the resulting DNA products, PCR 
reactions were run on 3% agarose gels, stained with ethidium 
bromide and imaged with UVP BioDoc-It Imaging Systems 
(Analytic Jena, Beverly, MA). DNA band intensities were 
quantified with ImageJ software (NIH, Bethesda, MD). The 
exon skipping induced by variants in this assay was calculated 
as percentage of skipped transcripts among total transcripts. 
Repeat transfection experiments were performed to confirm 
the consistency of results. Selected DNA products were gel- 
purified using QIAquick Gel Extraction Kit (Qiagen) and se- 
quenced at Facility for Biotechnology Resources, US Food 
and Drug Administration (Silver Spring, MD).
2.5 | In vitro translation assay
The effect of c.484C>A variant (p.R162R) on FIX global 
translation rates was assessed by performing in vitro trans­
lation assay. Assay was performed with Rabbit Reticulocyte 
Lysate (RRL) cell-free system (Promega) supplemented
with calf liver tRNAs as described earlier (Simhadri et al., 
2017).
3 | RESULTS
3.1 | In silico analysis using splice site tools
predicted high number of F9 exonic point 
variants to induce splicing dysregulation
We employed NNSplice, MES, SSF-like, and HSF tools to 
assess the effect of exonic disease-causing and neutral vari- 
ants on disruption of native splice sites and/or activation/ 
creation of cryptic splice sites. A total of 535 variants from 
our curated database (Table 1; Table S1) that included 409 
disease-causing non-synonymous variants, six disease-caus- 
ing synonymous variants, and 120 neutral variants (64 non- 
synonymous and 56 synonymous) were analyzed. We first 
assessed the strength of the native splice sites of all F9 exons 
predicted by the tools (Table 2). Our analysis showed that 
NNsplice and MES predicted a weak acceptor site for exon 4 
and weak donor site for exon 5. NNsplice assigns a score of 0 
to 1 for native splice sites. For exon 4 acceptor site, NNsplice 
reported a score of 0.22 against an average score of 0.97 
(±0.03) for remaining exons. Similarly, for exon 5 donor site, 
NNsplice reported a score of 0.21 against an average score of 
0.93 (±0.09) for other exons. MES assigns a score of 0 to 12 
for native splice sites. For exon 4 acceptor site, MES reported 
a score of 5.14 against an average score of 8.75 (±1.23) for 
remaining exons. Similarly, for exon 5 donor site, MES re- 
ported a score of 3 against an average score of 8.52 (±0.74) 
for other exons. SSF-like and HSF tools, which assign a score 
of 0-100 for splice sites reported relatively lower scores for 
acceptor and donor site of exon 4 and 5, respectively, but dif- 
ference in scores compared to other native sites was relatively 
low (Table 2). An additional in silico splice site tool, alter- 
native splice site predictor (ASSP) (http://wangcomputing. 
com/assp/) also reported relatively lower scores for acceptor 
site of exon 4 (2.56 vs. 9.9 ± 1.50 for other corresponding 
sites) and donor site of exon 5 (6.49 vs. 11.84 ± 1.17 for other 
corresponding sites), suggesting that these sites are possibly 
weak and less conserved.
In our study, as previously described in the Materials 
and Methods section, variants were considered to affect 
splicing upon weakening of native site (≥10% score de- 
crease) or activation/creation of a comparably strong cryp- 
tic site (≥90% of native score). Complete details of splice 
site score changes reported by in silico splice site predic- 
tion tools for F9 exonic disease-causing and neutral vari- 
ants analyzed in this study are provided in Table S2. Using 
these criteria mentioned above, NNsplice, MES, SSF-like, 
and HSF tools predicted 39, 36,44, and 89 variants, respec- 
tively, to affect splicing. Classification of the variants pre- 
dicted to affect splicing by variant type (non-synonymous,
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▼ ▼ 1 LlL i
Exon
NNSplice
(0-l)a
MaxEntScan
(0-12)
SpliceSite
Finder-like
(0-100)
Human
Splicing Finder 
(0-100)
NNSplice
(0-1)
MaxEnt
Scan (0-12)
SpiiceSiteFinder- 
Iike (0-100)
Human Splicing 
Finder (0-100)
1 N/Ab N/A N/A N/A 0.83 7.44 79.95 86.17
2 0.94 7.6 88.74 88.6 0.97 8.34 74.28 82.56
3 1 9.07 88.53 82.8 0.99 8.72 81.58 91.09
4 0.22 5.14 67.13 78.45 1 9.66 95.87 98.02
5 0.94 9.23 86.18 82.9 0.21 3 72.4 80.32
6 0.99 9.94 85.79 81.29 0.79 8.17 76.82 78.88
7 0.99 9.75 97.75 93.79 0.99 8.76 87.85 87.83
8 0.93 6.88 91.13 82.61 N/Ac N/A N/A N/A
aNumbers in parenthesis indicate the range of scores assigned to splice sites by individual tools. Lower number indicates weak or less conserved splice site and higher 
number indicates strong or highly conserved splice site.
bExon 1 lacks natural acceptor site. Hence, no score was calculated and N/A (not applicable) was shown.
cExon 8 lacks natural donor site. Hence, no score was calculated and N/A was shown.
synonymous, and neutral) and splicing dysregulation type 
(affecting native site or cryptic site) is provided in Tables 
3 and 4, respectively. Among the four tools, HSF predicted 
higher number of variants to affect splicing, which was 
primarily due to the prediction of higher number of acti- 
vation/creation of cryptic acceptor sites (Table 4). Further 
examination of the variants predicted to affect splicing re- 
vealed that 19 variants were predicted to affect splicing 
by all four tools and 28 variants were predicted to affect 
splicing by at least three tools (Figure 1). Commonly pre- 
dicted variants by all tools, included 14 non-synonymous 
variants, four synonymous variants, and one neutral vari- 
ant. Of these, nine non-synonymous and two synonymous 
variants disrupted native consensus splice sequences in 
exons (first and last two nucleotides of the exon; Figure 2). 
Of the six disease-causing synonymous variants analyzed 
in this study, four were predicted to affect splicing by all 
four tools and one was predicted to affect splicing by three 
tools except HSF. One synonymous variant (c.484C>A) 
was not predicted to affect splicing by any of the tools.
3.2 | In vitro minigene assays of selected 
variants revealed variable outcome of splicing 
dysregulation
To validate the predictions of the in silico splice site tools, 
in vitro minigene assays were performed for selected vari- 
ants. Details of variants selected for this assay, in silico 
predictions by splice site tools, and results from minigene 
assays are shown in Table 5 and Figure 3. Variants included 
in this analysis were primarily selected from exons 4,5, and 
6 which offer varied contexts of native splice sites, wherein 
exon 4 has weak acceptor site, exon 5 has weak donor site, 
and exon 6 has no weak native splice sites. The selected 
mutations included all: synonymous, non-synonymous, and 
neutral variants. In addition, we included variants that have 
variable effects on splice sites (disrupting native splice 
sites, activating/creating cryptic sites, or no effect).
In exon 4, we evaluated four disease-causing non-syn­
onymous variants: c.278A>G, c.316G>A, c.365G>T, and 
c.373G>A in comparison with wild-type exon 4 sequence. In
TABLE 3 Classification of F9 exonic disease-causing and neutral variants predicted to affect splicing by in silico splice site tools based on 
variant type
Variant type
Number of vari­
ants analyzed NNSplice MaxEntScan SpliceSiteFinder-like
Human
Splicing Finder
Disease-causing non-synonymous 
variants
409 29 27 35 73
Disease-causing synonymous 
variants
6 5 5 5 4
Neutral non-synonymous variants 64 1 1 1 4
Neutral synonymous variants 56 4 3 3 8
Total 535 39 36 44 89
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TABLE 4 Classification of F9 exonic disease-causing and neutral variants predicted to affect splicing by in silico splice site tools based on 
splicing dysregulation mechanism
Human
Mechanism NNSplice MaxEntScan SpliceSiteFinder-like Splicing Finder
Disruption of native acceptor site 2 2 1 1
Disruption of native donor site 13 13 10 10
Activation/creation of cryptic acceptor site 10 10 17 60
Activation/creation of cryptic donor site 14 11 16 18
Total 39 36 44 89
FIGURE 1 F9 exonic variants predicted to affect splicing by 
in silico splice site tools. Venn diagram shows the overlap between 
F9 exonic variants predicted to affect splicing by in silico splice site 
prediction tools employed in this study; NNsplice, MaxEntScan (MES), 
SpliceSiteFinder-like (SSF-like), and Human Splicing Finder (HSF)
the minigene assays, exon 4 reporter constructs should yield 
a 360 bp PCR product upon normal splicing (exon inclusion) 
and 246 bp PCR product in the event of exon skipping. In our 
study, exon 4 wild-type sequence and c.278A>G variant, that 
was predicted to increase native acceptor site strength and 
positively influence splicing, showed normal splicing with 
100% exon inclusion. C.316G>A and c.373G>A variants, 
that were predicted to create a new cryptic acceptor site of 
significant strength by SSF-like and HSF tools, showed 0 and 
1.74% of exon skipping, respectively. C.365G>T variant, that 
was predicted to activate a cryptic acceptor site by all four 
tools, showed 5.59% exon skipping.
In exon 5, we evaluated the following variants: c.423C>T, 
c.459G>A, c.465C>T, c.479G>T, c.479G>C, c.484C>A, 
and c.513A>G in comparison with wild-type exon 5 sequence. 
In the minigene assays, exon 5 reporter constructs should yield 
a 375 bp PCR product upon normal splicing and 246 bp PCR 
product in the event of exon skipping. In our study, exon 5
wild-type construct showed 34.31 exon skipping (Figure 3). 
This result was expected as exon skipping of the wild-type 
exon 5 sequence in both in vitro minigene assays and in vivo 
(human liver tissue) was reported in earlier studies (Balestra 
et al., 2016; Tajnik et al., 2016). The exon skipping observed 
for the wild-type sequence is likely due to a weak donor site as 
predicted by the tools. In exon 5, c.459G>A and c.484C>A are 
disease-causing synonymous variants. Of these, c.459G>A 
was predicted to activate a new cryptic donor site by three 
tools, excluding HSF, whereas c.484C>A was not predicted to 
affect splicing by all four tools. In our study, both c.459G>A 
and c.484C>A variants induced significant exon skipping 
(94.34% and 98.1%, respectively). C.423C>T and c.513A>G 
are synonymous neutral variants that were predicted to create 
a cryptic donor site by majority of tools. Interestingly, neutral 
variants, c.423C>T and c.513A>G, showed higher exon skip- 
ping than wild-type sequence with rates of 52.5 and 41.35%, 
respectively. c.465C>T is also a synonymous neutral variant 
that was not predicted to affect splicing by all four tools. This 
variant showed 37.66% exon skipping which was similar to 
exon skipping observed for the wild-type sequence. Finally, 
c.479G>T and c.479G>C are non-synonymous disease-caus- 
ing variants. Of these, c.479G>T was predicted to create a 
new cryptic donor site by all four tools, whereas c.479G>C 
was predicted to create a new cryptic donor site by SSF-like 
tool only. In the minigene assay, c.479G>T showed signifi- 
cant exon skipping (54.73%) as well as mis-splicing (18.42%) 
with a loss of 43 nucleotides in exon that was confirmed by 
subsequent sequencing of mis-spliced product (Table 6). On 
the other hand, c.479G>C showed 41.65% exon skipping.
In exon 6, we evaluated the following variants: c.535G>A, 
c.677G>A, c.711A>G, c.715C>T, c.719G>T, and c.723G>A 
in comparison with wild-type exon 6 sequence. In the minigene 
assays, exon 6 reporter constructs should yield a 449 bp PCR 
product upon normal splicing and 246 bp PCR product in the 
event of exon skipping. Of the variants analyzed, c.535G>A, 
c.677G>A, c.715C>T, and c.719G>T are non-synonymous 
disease-causing variants that were predicted to create/activate 
cryptic acceptor sites predominantly by SSF-like and HSF 
tools. In minigene assay, these variants showed normal splic- 
ing with 100% exon inclusion similar to wild-type sequence.
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FIGURE 2 Location of F9 exonic splicing variants predicted to affect splicing by all in silico splice site tools. Image shows the location of 
F9 exonic variants that were predicted to affect splicing by all four in silico splice site tools (NNsplice, MaxEntScan, SpliceSiteFinder-like, and 
Human Splicing Finder). Bars indicate the number of variants identified at each location
In exon 6, c.711A>G and c.723G>A are synonymous disease- 
causing variants. Of these, c.711A>G was predicted to activate 
a new cryptic donor site by all four tools. In our study, this vari­
ant induced mis-splicing with the loss of 17 nucleotides in the 
exon (Table 6). The second synonymous variant, c.723G>A, 
disrupts natural donor site consensus sequence and was pre- 
dicted to significantly lower its strength by all four tools. In ad­
dition, SSF-like and HSF tools predicted this variant to create 
new cryptic donor site 4 nucleotides upstream of native donor 
site (Table 6). In the minigene assay, c.723G>A induced mis- 
splicing as predicted by SSF-like and HSF tools. Mis-splicing 
induced by both c.711A>G and c.723G>A variants was con- 
firmed by subsequent sequencing of PCR products.
3.3 | In silico analysis using SRE prediction
tools revealed the contribution of SRE 
disruption to splicing dysregulation
Results from minigene assays showed that for some variants 
that were predicted to activate/create a cryptic acceptor site or 
donor site (e.g., c.365G>T, c.423C>T, and c.459G>A), the 
predominant effect on splicing was exon skipping rather than 
mis-splicing from the use of predicted cryptic splice sites. Also, 
c.484C>A, a disease-causing synonymous variant that was not 
predicted to effect splicing by all splice site prediction tools 
showed significant exon skipping. These results suggested a 
possible role of SREs in the dysregulation of splicing by these 
variants. To assess the dysregulation of SREs by the exonic 
variants under study, we calculated the score changes for vari- 
ant sites in comparison with native sequence using ESRseq, 
HEXplorer methods, and the EX-SKIP tool (Table 5). For 
variant sequences, a net negative score change calculated by
ESRseq and HEXplorer methods and a ratio of > 1 by EX-SKIP 
tool indicates the disruption of ESEs and/or creation of ESSs 
and predicts increased exon skipping. We excluded c.278A>G 
and c.723G>A variants from this analysis due to their loca- 
tion within the consensus splice site sequences. Individually, 
for variants c.365G>T, c.423C>T, c.459G>A, c.479G>T, and 
c.484C>A which showed relatively higher exon skipping in 
their respective exons, the numbers reported by all three meth- 
ods suggested increased exon skipping. Also, for the c.373G>A 
variant in exon 4 that showed no exon skipping, numbers re- 
ported by all tools were in agreement suggesting a lack of dys- 
regulation of SREs. For rest of the variants, predictions were 
inconsistent, especially for exon 6 variants. Among the individ- 
ual tools, overall score changes calculated by ESRseq method 
were in general agreement with the increased exon skipping 
observed for variants in exons 4 and 5. This finding need to 
be viewed with the consideration that our dataset, which was 
selected to represent various criteria of variants for minigene 
assay, was small and may not be suitable for measuring overall 
tendency or statistical association. Additionally, some variants 
(c.479G>T, c.711A>G, and c.723G>A) were involved in ad- 
ditional splicing dysregulation of activation/creation of cryptic 
splice sites and subsequent mis-splicing.
3.4 | In vitro translation assay revealed 
additional disease induction mechanism of 
c.484C>A synonymous variant
In addition to splicing, synonymous variants were reported 
to induce disease phenotype through altered mRNA and 
protein characteristics (Hunt et al., 2014). The lack of pre- 
dicted effect of c.484C>A mutation on splicing by in silico
T A B L E 5 F9 exonic variants assessed by minigene assays and in silico predictions of their effect on splicing regulation
Relative distance to Exon skip-
Human EX- ping based
Nucleotide
change Exon
Mutation
type
Disease-
causing
Acceptor
site
Donor
site
NN
splice
MaxEnt
Scan
Splicing
Finder
SpliceSite
Finder-like
AESRseq
score
ΔHEXplorer
score
SKIP
ratio
on minigene 
assay (%)h Comments
c.278A>G 4 Non-syna Yes 0 113 NAC NA NA NA 0 Increases native 
acceptor site
score
c.316G>A 4 Non-syn. Yes 38 75 ned ne CAe CA -0.764 30.14 0.966 1.74 ±0.52
c.365G>T 4 Non-syn. Yes 87 26 CA CA CA CA -2.395 -105.18 1.241 5.59 ±0.29
c.373G>A 4 Non-syn. Yes 95 18 ne ne CA CA 0.22 3.2 0.983 0
c.423C>T 5 Syn.b No 31 97 CDf CD CD CD -0.894 -43.84 1.058 52.5 ± 0.24 Wild-type exon 5 
sequence showed 
34.31 ± 1.15% 
exon skipping
c.459G>A 5 Syn. Yes 67 61 CD CD ne CD -0.962 -30.13 1.115 94.34 ± 0.29
c.465C>T 5 Syn. No 73 55 ne ne ne ne 0.529 -42.25 1.327 37.66 ± 1.18
c.479G>T 5 Non-syn. Yes 87 41 CD CD CD CD -1.356 -15.42 1.173 54.73 ± 1.03 18.42 ±0.77% 
mis-splicing
c.479G>C 5 Non-syn. Yes 87 41 ne ne ne CD 0.255 18.22 0.981 41.65 ±0.88
c.484C>A 5 Syn. Yes 92 36 ne ne ne ne -2.202 -79.82 1.058 98.1 ±0.40
c.513A>G 5 Syn. No 121 7 CD CD CD ne -1.375 -30.58 1.096 41.35 ±0.21
c.535G>A 6 Non-syn. Yes 14 188 ne ne CA CA -2.96 -46.36 1.035 0
c.677G>A 6 Non-syn. Yes 156 46 ne ne CA CA -2.012 -13.58 0.965 0
c.711A>G 6 Syn. Yes 190 12 CD CD CD CD -0.862 -5 1 100%
mis-splicing
c.715C>T 6 Non-syn. Yes 194 8 ne ne CA CA 0.812 -18.65 1.053 0
c.719G>T 6 Non-syn. Yes 198 4 CA ne CA CA -1.301 17.68 1.035 0
c.723G>A 6 Syn. Yes 202 0 ND8 ND ND + CD ND + CD 100% Decreases native
mis-splicing donor site score
aNon-synonymous.
bSynonymous.
cAffects native acceptor site.
dNo predicted effect on splicing.
eActivation or creation of cryptic acceptor site.
fActivation or creation of cryptic donor site.
8Affects native donor site.
hNumbers indicate exon skipping percentage (±SD) for each mutation (Figure 3).
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FIGURE 3 In vitro minigene analysis of select F9 variants in exons 4, 5, and 6. Representative agarose gel image showing the PCR 
amplification products of the studied F9 variants. Reporter minigene constructs were transfected into HEK293 cells and splicing pattern was 
assessed by PCR amplification of cDNA generated from total RNA. Expected sizes of PCR amplified products for exon 4, 5, and 6 reporter 
constructs were 360, 375, and 449 bp, respectively, in the event of normal splicing (exon inclusion) and 246 bp in the event of exon skipping. Exon 
skipping induced by individual variants was calculated using ImageJ software and numbers were shown in Table 5. The characteristics of tested 
variants with regard to disease-causing (+) or not (—), synonymous (+) or not (—), number of tools (out of four in silico splice site tools; NNsplice, 
MaxEntScan, SpliceSiteFinder-like, and Human Splicing Finder) that predicted splice site dysregulation, the extent of exon skipping and/or mis- 
splicing in minigene assays, and their exonic locations are indicated below
splice site tools in our preliminary analysis prompted us to 
assess its impact on translation rate using in vitro translation 
assay. In this assay, c.484C>A showed significant reduc- 
tion in the translation rate of variant F9 mRNA (Figure 4).
4 | DISCUSSION
In this study, we analyzed a curated dataset of 535 F9 exonic 
variants including 415 disease-causing (409 non-synony- 
mous and six synonymous) and 120 neutral variants (64 non- 
synonymous and 56 synonymous) for their effect on splicing 
using in silico splice site prediction tools and further evalu- 
ated selected variants using in vitro minigene assays and in 
silico SRE prediction tools.
Analysis of strength of natural splice sites in the eight 
exons of the F9 gene indicated that exon 4 and 5 carry weak 
acceptor and donor site, respectively (Table 2). The scores 
assigned by NNsplice, MES, and ASSP tools to these sites 
were lower compared to other corresponding F9 splice 
sites. The in silico splice site tools employed in this study, 
NNsplice, MES, SSF-like, and HSF, predicted 39, 36,44, and 
89 variants, respectively, to affect splicing via disruption of 
native splice sites or creation/activation of cryptic splice sites 
(Tables 3 and 4). Of the 19 variants that were predicted by 
all four tools, 11 were located within the consensus splice se- 
quences in exons (first and last two of the exonic nucleotides; 
Figure 2) affecting native splice sites. The splice site tools
perform relatively better within consensus splice sites when 
compared to distantly located variants (Jian, Boerwinkle, & 
Liu, 2014). A total of 15 variants in consensus splice sites 
were analyzed in this study. The remaining four variants in 
the consensus sequences were not predicted to affect splicing 
by NNsplice, SSF-like, and HSF tools as score changes were 
lower than 10%. These results suggested that the prediction 
tools are mostly in agreement with variants located in con- 
sensus splice site sequences. Also, these variants are more 
likely to be involved in splicing events.
We evaluated a selected list of variants including four 
synonymous, 10 non-synonymous and three neutral variants 
from exons 4, 5, and 6 using in vitro minigene assays (Table 
5). This carefully chosen set of variants, which represent 
exons of varied natural splice site strength, both disease-caus- 
ing and neutral variants and variable mechanism of splicing 
dysregulation, showed interesting outcomes in the minigene 
assays. All the synonymous disease-causing variants studied 
by minigene assay in this study (c.459G>A and c.484C>A 
in exon 5 and c.711 A>G and c.723G>A in exon 6) showed 
splicing dysregulation. Of these, c.484C>A was not predicted 
to affect splicing by the splice site prediction tools, but further 
examination by SRE prediction tools suggested disruption of 
ESEs and/or creation of ESSs and increased potential of exon 
skipping. Results from the minigene assay for c.484C>A 
were in agreement with this last prediction. The c.723G>A 
variant alters the last nucleotide of exon 6 disrupting native 
5'ss consensus sequence. All four splice site prediction tools
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FIGURE 4 In vitro translation analysis of c.484C>A (p.R162R) 
variant. Panel (a) shows the representative autoradiogram of FIX wild- 
type (WT) and FIX p.R162R (c.484C>A) in vitro translation products. 
Panel (b) shows the graphical representation of intensities of in vitro 
translation products. Error bars represent SD values
predicted the disruption of native donor site and reported 
lower scores. SSF-like and HSF tools have additionally pre- 
dicted the activation of an upstream (four nucleotides) cryptic 
donor site. This activated cryptic donor site involved non- 
canonical splice site pair GC-AG which was appreciated to 
occur at a very low frequency (<1%) compared to commonly 
used (>99%) canonical splice site pair GT-AG (Burset, 
Seledtsov, & Solovyev, 2000). The failure of NNsplice and 
MES tools in identification of the cryptic donor site activa- 
tion by c.723G>A was probably due to noninclusion of non- 
canonical splice site pairs in their prediction model (Reese 
et al., 1997; Yeo & Burge, 2004). Two other synonymous 
variants in our curated database were also predicted to affect 
splicing either by disruption of consensus splice site sequence 
(c.87A>G) or activation of a cryptic donor site with a score 
higher than native donor site (c.153A>G). Overall, all six 
disease-causing synonymous variants analyzed in this study 
seem to induce splicing dysregulation. These results further 
show that splicing dysregulation is a common disease-induc- 
ing mechanism of synonymous variants (Hunt et al., 2014). 
However, growing literature evidence suggests that synony- 
mous variants can cause disease phenotype by several other 
mechanisms including altered mRNA structure and stability, 
miRNA binding, and altered codon usage affecting protein 
translation and folding (Athey et al., 2017; Bartoszewski et al., 
2010; Hunt et al., 2014; Kimchi-Sarfaty et al., 2006; Salzman 
& Weidhaas, 2011). Here, the c.484C>A synonymous vari- 
ant showed significant reduction in the global translation rate
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compared to wild-type (Figure 4) in in vitro translation assay. 
While the very high rate of exon skipping caused by this vari- 
ant seems to be the major mechanism of disease induction, 
diminished translation rate of the mature mRNA likely has a 
compounding effect. Recently, the c.459G>A variant in F9, 
which showed dysregulation of splicing in our study and oth- 
ers (Tajnik et al., 2016), was reported to alter protein confir- 
mation via altered translation kinetics and result in decreased 
specific activity of FIX (Simhadri et al., 2017) suggesting that 
alternative or concomitant mechanisms of disease induction 
for synonymous variants should not be ignored.
The non-synonymous variants tested in minigene assays 
included four in exons 4 and 6 and two in exon 5. Except 
for the c.278A>G variant in exon 4, all other variants were 
located outside consensus splice site sequences. In our study, 
several of these non-synonymous variants (e.g., c.316G>A 
and c.365G>T in exon 4, c.479G>T and c.479G>C in exon 
5) showed increased exon skipping relative to respective 
wild-type sequences. Interestingly, in addition to exon skip- 
ping, c.479G>T also induced mis-splicing through activation 
of cryptic donor site. These results underscore how splicing 
dysregulation can contribute partially or wholly to disease 
phenotype induced by non-synonymous variants. All the 
neutral variants tested by minigene assays were synonymous 
and located in exon 5. Of these, c.423C>T and c.513A>G 
variants showed increased exon skipping relative to wild- 
type sequence. The partial dysregulation of splicing induced 
by these neutral variants may not be sufficient to lower the 
serum FIX levels (to <40%) to induce hemophilia B. Overall, 
results from our study show that F9 exonic non-synonymous 
and neutral variants located outside consensus splice site 
sequences can induce splicing dysregulation either through 
activation/creation of cryptic splice sites and/or disruption of 
SREs. This finding is in agreement with recent literature that 
reported the prevalence of exonic splicing variants with up 
to 7% of exonic variants being predicted to disrupt splicing 
(Caminsky et al., 2015; Soukarieh et al., 2016).
An important observation from the minigene assay data 
was that some of the variants that were predicted to acti- 
vate a cryptic donor site showed mis-splicing (c.479G>T, 
c.711A>G, and c.723G>A), whereas none of the variants 
that were predicted to activate a cryptic acceptor site showed 
mis-splicing (c.365G>T, c.719G>T etc.). Branch point rec- 
ognition plays an important role in acceptor site selection 
during pre-mRNA splicing (Mercer et al., 2015). The splice 
site prediction tools typically model for consensus sequence of 
acceptor sites in isolation from branch point site and its adja- 
cent polypyrimidine tract sequences, which makes predictions 
for cryptic acceptor sites less reliable. Results from minigene 
assays in our study were in agreement with this observation.
Additionally, variants in exons 4 and 5 readily induced 
exon skipping compared to exon 6 variants. Variants in exon 
6 showed mis-splicing or no effect on splicing. Furthermore,
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within exons 4 and 5, the level of exon skipping was higher for 
variants in exon 5 compared to exon 4. As mentioned, exon 
4 and 5 seem to have weak acceptor and donor site, respec- 
tively. Previous studies suggested that SR proteins improve 
the inclusion of exons with weak splice sites through their 
action on ESEs and in the event of their disruption, exons 
with weak splice sites are more susceptible to splicing de- 
fects (Grodecka, Buratti, & Freiberger, 2017; Roca, Krainer, 
& Eperon, 2013). Although this is a small dataset, our results 
suggest that the exon skipping events observed for variants in 
exons 4 and 5 are a result of disruption of SREs in the context 
of weak splice sites.
In our study, in silico splice site prediction tools were 
predictive of the activation of cryptic donor sites by vari- 
ants located outside consensus sequences in exon se- 
quences (c.479G>T and c.711A>G). For some variants, 
the predicted cryptic splice sites did not translate into mis- 
splicing and a subsection of these showed variable levels 
of exon skipping (e.g., c.365G>T and c.423C>T). For 
the variants that showed relatively higher levels of exon 
skipping (c.365G>T, c.423C>T, c.459G>A, c.479G>T, 
and c.484C>A), in silico SRE prediction tools predicted 
exon skipping due to disruption of ESEs and/or creation 
of ESSs. The exon skipping observed for c.484C>A seems 
to be clearly due to disruption of SREs as no cryptic splice 
site activation was predicted by splice site tools. However, 
for remaining variants, whether the observed exon skipping 
was primarily due to disruption of SREs or a combination 
of creation/activation of a competitive cryptic splice sites 
and disruption of SREs were not clear. Overall, our results 
indicate that splice site and SRE prediction tools used in 
tandem provide a better prediction of splicing dysregula- 
tion induced by exonic variants. However, as one would 
expect these tools were not always correctly predictive of 
the splicing dysregulation as we observed for several of the 
exon 6 variants. Also, the net outcome of splicing dysreg- 
ulation differed for variants across exons and not always 
predictable by in silico tools as it will depend on several 
additional factors including location and strength of cryptic 
splice sites, strength of corresponding native splice sites, 
and density of SREs (Caminsky et al., 2015; Grodecka et 
al., 2017). In this regard, outcome of splicing dysregulation 
can be best assessed by performing minigene assay of vari- 
ant in the context of native exon sequence.
In conclusion, our study suggests that splicing dysreg- 
ulation may contribute to the pathogenicity of majority of 
synonymous variants and several non-synonymous variants 
in F9. The in silico splice site and SRE prediction tools 
when used in tandem more accurately predicted spicing 
dysregulation induced by such variants. The net effect of 
point variants on splicing dysregulation is context depen- 
dent and can be difficult to predict by in silico prediction 
tools. When primary tissue samples are not available, as is
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often the case, minigene assays remain a straightforward 
approach to assess novel variants for splicing effects. While 
the findings in this work were drawn from studying variants 
in F9, we anticipate that these findings may be recapitulated 
upon careful analysis of variants in other genes as well.
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Splicing dysregulation is considered the primary disease-inducing mechanism of synonymous variants, but its contribution to 
the disease phenotype of non-synonymous variants is underappreciated. Through the analysis of F9 exonic point variants using 
a series of in silico and in vitro splicing analysis tools, we show that while synonymous variants primarily cause disease via 
splicing dysregulation, additional mechanisms such as altered translation rate also play an important role. Importantly, splicing 
dysregulation is likely to contribute to the disease phenotype of several non-synonymous variants.
